362 related articles for article (PubMed ID: 33720664)
1. Payer strategies to ensure access to care for individuals with opioid use disorder during COVID-19.
Bachireddy C; Terplan M
Am J Manag Care; 2021 Mar; 27(3):91-92. PubMed ID: 33720664
[TBL] [Abstract][Full Text] [Related]
2. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
Peckham AM; Ball J; Colvard MD; Dadiomov D; Hill LG; Nichols SD; Tallian K; Ventricelli DJ; Tran TH
Am J Health Syst Pharm; 2021 Mar; 78(7):613-618. PubMed ID: 33411894
[TBL] [Abstract][Full Text] [Related]
3. Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder: A Cohort Study.
Larochelle MR; Wakeman SE; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
Med Care; 2020 Oct; 58(10):919-926. PubMed ID: 32842044
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 and treating incarcerated populations for opioid use disorder.
Donelan CJ; Hayes E; Potee RA; Schwartz L; Evans EA
J Subst Abuse Treat; 2021 May; 124():108216. PubMed ID: 33288348
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and current clinical practices of opioid treatment programs in the United States.
Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
[TBL] [Abstract][Full Text] [Related]
6. Medication Treatment of Adolescent Opioid Use Disorder in Primary Care.
Carney BL; Hadland SE; Bagley SM
Pediatr Rev; 2018 Jan; 39(1):43-45. PubMed ID: 29292291
[No Abstract] [Full Text] [Related]
7. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
[No Abstract] [Full Text] [Related]
8. Challenges and Opportunities for the Use of Medications to Treat Opioid Addiction in the United States and Other Nations of the World.
Parrino MW; Maremmani AG; Samuels PN; Maremmani I
J Addict Dis; 2015; 34(2-3):255-62. PubMed ID: 26110357
[TBL] [Abstract][Full Text] [Related]
9. The payer's role in addressing the opioid epidemic: It's more than money.
Molfenter T; McCarty D; Jacobson N; Kim JS; Starr S; Zehner M
J Subst Abuse Treat; 2019 Jun; 101():72-78. PubMed ID: 31174716
[TBL] [Abstract][Full Text] [Related]
10. Medication-Assisted Treatment for Opioid-Use Disorder.
Oesterle TS; Thusius NJ; Rummans TA; Gold MS
Mayo Clin Proc; 2019 Oct; 94(10):2072-2086. PubMed ID: 31543255
[TBL] [Abstract][Full Text] [Related]
11. A health crisis within a health crisis: Opioid access in the COVID-19 pandemic.
Narayan A; Balkrishnan R
Subst Abus; 2021; 42(2):148-152. PubMed ID: 33849399
[TBL] [Abstract][Full Text] [Related]
12. Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.
Burns RM; Pacula RL; Bauhoff S; Gordon AJ; Hendrikson H; Leslie DL; Stein BD
Subst Abus; 2016; 37(1):63-9. PubMed ID: 26566761
[TBL] [Abstract][Full Text] [Related]
13. Overview of Drugs Used to Treat Opioid Use Disorder.
Aschenbrenner DS
Am J Nurs; 2018 Aug; 118(8):25. PubMed ID: 30048283
[No Abstract] [Full Text] [Related]
14. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
Cochran G; Bruneau J; Cox N; Gordon AJ
Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
[TBL] [Abstract][Full Text] [Related]
15. Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women.
Tran TH; Griffin BL; Stone RH; Vest KM; Todd TJ
Pharmacotherapy; 2017 Jul; 37(7):824-839. PubMed ID: 28543191
[TBL] [Abstract][Full Text] [Related]
16. The relationship between dissociative symptoms and the medications used in the treatment of opioid use disorder.
Gainer DM; Crawford TN; Fischer KB; Wright MD
J Subst Abuse Treat; 2021 Feb; 121():108195. PubMed ID: 33357605
[TBL] [Abstract][Full Text] [Related]
17. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
18. TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19.
Pena E; Ahmed S
Addiction; 2020 Oct; 115(10):1978-1979. PubMed ID: 32447795
[No Abstract] [Full Text] [Related]
19. Using telehealth to improve buprenorphine access during and after COVID-19: A rapid response initiative in Rhode Island.
Clark SA; Davis C; Wightman RS; Wunsch C; Keeler LAJ; Reddy N; Samuels EA
J Subst Abuse Treat; 2021 May; 124():108283. PubMed ID: 33771282
[TBL] [Abstract][Full Text] [Related]
20. A Community Partnership to Improve Access to Buprenorphine in a Homeless Population.
Leo P; Gastala N; Fleurimont J; Messmer S; Maes P; Richardson J; Neeb C; Stackhouse N; Koruba S; Watson DP
Ann Fam Med; 2021; 19(1):85. PubMed ID: 33431401
[No Abstract] [Full Text] [Related]
[Next] [New Search]
